NCT07007559 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT07007559
Title	ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies (ASPEN-09)
Acronym	ASPEN-09
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	ALX Oncology Inc.
Indications	Her2-receptor positive breast cancer colorectal cancer
Therapies	Capecitabine + Trastuzumab Gemcitabine + Trastuzumab Trastuzumab + Vinorelbine Paclitaxel + Trastuzumab Eribulin + Trastuzumab Evorpacept + Trastuzumab + Vinorelbine Cetuximab + Evorpacept + Fluorouracil + Irinotecan + Leucovorin Eribulin + Evorpacept + Trastuzumab Evorpacept + Gemcitabine + Trastuzumab Evorpacept + Paclitaxel + Trastuzumab Capecitabine + Evorpacept + Trastuzumab
Age Groups:	adult \| senior
Covered Countries	USA

Additional content available in CKB BOOST